House Passes Bill to Reauthorize FDA Pediatric Priority Review Voucher Program

The U.S. House of Representatives has passed a bill reauthorizing the Food and Drug Administration’s (FDA) pediatric priority review voucher program. The program, which incentivizes the development of treatments for rare pediatric diseases, received support from both patient advocacy groups and industry organizations. The legislation now moves to the Senate for further consideration.

The pediatric priority review voucher pathway allows pharmaceutical companies to receive expedited FDA reviews for their products targeting rare childhood illnesses. Companies can use these vouchers for their own drug applications or sell them to other developers. Advocates argue that the program encourages innovation in addressing unmet medical needs among children with rare conditions. While the House’s approval marks a significant step forward, final enactment depends on Senate approval in upcoming sessions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

International Collaboration Accelerates Generic Drug Development, Improves Treatment Access Researchers Map Atomic Structure of Midnolin Protein Linked to B-Cell Cancers Using Cryo-Electron Microscopy Trump Administration Plans Rule to Align U.S. Drug Prices with Costs in Comparable Nations Patient in Intellia Therapeutics Gene-Editing Trial for Transthyretin Amyloidosis Dies

Author

GOAI